Novocure Ltd. (NVCR) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Novocure Ltd. (NVCR:NASDAQ), powered by AI.

Current Price
$17.49
P/E Ratio
-14.3
Market Cap
1.9B
Sector
Healthcare
What is the Novocure Ltd. stock price forecast?

Novocure Ltd. is currently trading at $17.49. View real-time AI analysis on Alpha Lenz.

What is Novocure Ltd. insider trading activity?

View the latest insider trading data for Novocure Ltd. on Alpha Lenz.

What is Novocure Ltd.'s P/E ratio?

Novocure Ltd.'s P/E ratio is -14.3.

Novocure Ltd.

NASDAQ · NVCR
$17.49-0.11(-0.63%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Novocure Ltd.'s future dividend policy...
Alpha Chat Insight

Novocure Ltd. trades at a P/E of -14.3 (undervalued) with modest ROE of -38.9%.

Ask for details

Company Overview

Novocure Ltd. is a medical device company specializing in innovative cancer treatment therapies. The company's primary focus is the development and commercialization of Tumor Treating Fields (TTFields) therapy, a groundbreaking method that uses electric fields to disrupt cancer cell division. This non-invasive treatment is particularly aimed at combating aggressive forms of cancer, including glioblastoma and mesothelioma. With a commitment to advancing science and technology in oncology, Novocure operates within the healthcare sector, interfacing with both medical professionals and patients. Its contributions are critically significant, as it seeks to offer alternative options where traditional treatments like chemotherapy may be less effective. Headquartered in Saint Helier, Jersey, Novocure serves a global market, striving to enhance patient outcomes through rigorous clinical research and development. Its innovative approach positions Novocure as a leader in the specialty cancer treatment domain, impacting the larger biotechnology and medical device industries."

CEOMs. Ashley Cordova
SectorHealthcare
IndustryMedical Devices
Employees1,488

Company Statistics

FY 2025

Profile

$1.95BMarket Cap
$655.35MRevenue
0.00Shares Out
1,488Employees

Margins

74.54%Gross
-15.30%EBITDA
-23.47%Operating
-20.79%Pre-Tax
-20.79%Net

Valuation

-14.31P/E
5.73P/B
2.98EV/Sales
-20.99EV/EBITDA
-25.76P/FCF

Growth (CAGR)

6.81%Rev 3Yr
5.80%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-13.32%ROA
-38.89%ROE
-11.66%ROIC

Financial Health

$93.55MCash & Cash Equivalents
$370.31MNet Debt
136.24%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Novocure Ltd. (ticker: NVCR) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 1,488 employees. Market cap is $1.9B.

The current price is $17.49 with a P/E ratio of -14.31x and P/B of 5.73x.

ROE is -38.89% and operating margin is -23.47%. Annual revenue is $655M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Novocure Ltd. (NVCR) Stock Forecast 2026 $17.49 — Price, Financials & Analyst Targets | Alpha Lenz